OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM5.07.Submission
| of Matters to a Vote of Security Holders. |
On June15, 2017, OPKO Health, Inc. (the Company) held its 2017
Annual Meeting of Stockholders (the Annual Meeting). Below is a
summary of the proposal and corresponding vote.
| 1. |
All eight nominees were elected to the Board of Directors with each director receiving votes as follows: |
| Election of Directors | For | Withheld | ||||||
|
Phillip Frost, M.D. |
313,587,917 | 34,590,555 | ||||||
|
Jane H. Hsiao, Ph.D. |
305,500,426 | 42,678,046 | ||||||
|
Steven D. Rubin |
304,154,561 | 44,023,911 | ||||||
|
Richard M. Krasno, Ph.D. |
344,682,759 | 3,495,713 | ||||||
|
Richard A. Lerner, M.D |
286,997,023 | 61,181,449 | ||||||
|
John A. Paganelli |
291,162,570 | 57,015,902 | ||||||
|
Richard C. Pfenniger, Jr. |
333,531,789 | 14,646,683 | ||||||
|
Alice Lin-Tsing Yu, M.D., Ph.D. |
296,686,376 | 18,792,096 |
| 2. |
The approval, on a non-binding advisory basis, of the compensation of the named executive officers of the Company (Say On Pay) as disclosed in the Companys Proxy Statement for the Annual Meeting. The votes on this proposal were as follows: |
|
For |
Against | Abstain | ||
|
316,825,919 |
30,329,801 | 1,022,752 |
| 3. |
The selection of one year, on a non-binding advisory basis, as the frequency with which the stockholders are provided a non-binding advisory vote on Say on Pay in future years. The votes on this proposal were as follows: |
|
1 Year |
2 Years | 3 Years | Abstain | |||
|
309,086,990 |
692,622 | 37,254,593 | 1,144,267 |
Based on this result and in accordance with the previous
recommendation of the Companys Board of Directors, the Company
will hold a non-binding, advisory vote on Say On Pay every year.
There were no broker non-votes for the proposals. No other
matters were considered or voted upon at the meeting.
| ITEM7.01.Regulation | FD Disclosure. |
On June15, 2017, the Company held its Annual Meeting of
Stockholders. Copies of the presentations presented at the Annual
Meeting are furnished with this Current Report on Form 8-K as
Exhibit99.1.
Statements are made in the presentations which are not historical
are forward-looking statements that reflect managements current
views with respect to future events and performance and may
include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying
assumptions. Such statements are subject to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. The fact that these presentation materials are being
furnished should not be deemed an admission as to the materiality
of any information contained in the materials.
The information contained in Item7.01 to this Current Report on
Form 8-K and
Exhibit99.1 shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing by the Company
under the Act, unless expressly stated otherwise.
| ITEM9.01. | Financial Statements and Exhibits. |
(d)
Exhibits
|
Exhibit Number |
Description |
|
| 99.1 |
OPKO Presentation 2017 Annual Meeting of Stockholders held June15, 2017. |
About OPKO Health, Inc. (NASDAQ:OPK)
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.
